Opicapone in Parkinson’s disease: a real-world, multicenter, retrospective study to identify patient characteristics for sustained treatment benefit
Journal of Neural Transmission · 2026
DOI: 10.1007/s00702-025-03000-3 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Neural Transmission, 2026. Verfasst von Clelia Pellicano und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Neuropsychiatry, Santa Lucia Foundation IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Parkinson Disease, Oxadiazoles, Catechol O-Methyltransferase Inhibitors, Antiparkinson Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bial.
Abstract (Originalsprache)
Fluctuations often complicate the course of Parkinson’s disease (PD). The third-generation catechol- O -methyltransferase inhibitor, opicapone, is safe and effective in patients with PD motor fluctuations, whether long-standing or earlier onset. Real-world data are needed to identify the most appropriate candidates for initiating and sustaining therapy with opicapone. To evaluate the long-term outcomes and identify predictors for safer and prolonged use of opicapone. This real-world, longitudinal, multicenter, retrospective study collected data on the demographics, medical history, motor subtype, motor severity, cognitive and psychiatric disorders at baseline when opicapone was introduced as add-on therapy and at the last follow-up. Discontinuation rates and main causes were recorded. Clinical features of patients who continued/discontinued were compared to identify predictors for drug discontinuation and define successful long-term outcomes. Of the 178 enrolled patients, 85% (35% of them female) continued opicapone for a mean of 30.2 ± 19.64 months. The remaining 15% (13.4% female) discontinued opicapone within 8.9 ± 11.30 months due to disabling dyskinesia, hypotension, gastrointestinal disorders, or psychiatric disturbances. Continuers were younger at baseline than those who discontinued, but clinical-demographic features did not predict continuing opicapone therapy. Continuers had significantly lower Hoehn and Yahr scale scores and fewer night-time OFF periods compared with discontinuers, whereas levodopa equivalent daily dose and burden of motor and neuropsychiatric complications were similar. Continued opicapone therapy was associated with less motor impairment and reduced night-time OFF. Safety and long-term tolerability were higher in younger patients with a tendency to milder motor severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Neuropsychiatry, Santa Lucia Foundation IRCCS, Rome, Italy.
- Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy. daniele.belvisi@uniroma1.it.
- Department of Neurology and Clinical Neurophysiology, IRCCS Neuromed, Pozzilli, Italy. daniele.belvisi@uniroma1.it.
- Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy.
- Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
- Department of Neuroscience, Istituto Superiore Di Sanità, Rome, Italy.
Förderung
- Bial
Zitieren
APA
Pellicano, C., Belvisi, D., Bovenzi, R., Costanzo, M., De Bartolo, M. I., Sommaruga, F., Blandino, J., Modugno, N., Piras, F., Pierantozzi, M., Stefani, A., Fabbrini, G., & Schirinzi, T. (2026). Opicapone in Parkinson’s disease: a real-world, multicenter, retrospective study to identify patient characteristics for sustained treatment benefit. Journal of Neural Transmission. https://doi.org/10.1007/s00702-025-03000-3
Vancouver
Pellicano C, Belvisi D, Bovenzi R, Costanzo M, De Bartolo MI, Sommaruga F, et al. Opicapone in Parkinson’s disease: a real-world, multicenter, retrospective study to identify patient characteristics for sustained treatment benefit. Journal of Neural Transmission. 2026. doi:10.1007/s00702-025-03000-3
BibTeX
@article{Pellicano2026,
author = {Pellicano, Clelia and Belvisi, Daniele and Bovenzi, Roberta and Costanzo, Matteo and De Bartolo, Maria I and Sommaruga, Francesca and Blandino, Jessica and Modugno, Nicola and Piras, Fabrizio and Pierantozzi, Mariangela and Stefani, Alessandro and Fabbrini, Giovanni and Schirinzi, Tommaso},
title = {Opicapone in Parkinson’s disease: a real-world, multicenter, retrospective study to identify patient characteristics for sustained treatment benefit},
journal = {Journal of Neural Transmission},
year = {2026},
doi = {10.1007/s00702-025-03000-3}
}
EUVIMED